AU2010240717A1 - Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline - Google Patents
Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline Download PDFInfo
- Publication number
- AU2010240717A1 AU2010240717A1 AU2010240717A AU2010240717A AU2010240717A1 AU 2010240717 A1 AU2010240717 A1 AU 2010240717A1 AU 2010240717 A AU2010240717 A AU 2010240717A AU 2010240717 A AU2010240717 A AU 2010240717A AU 2010240717 A1 AU2010240717 A1 AU 2010240717A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- iii
- chloro
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17199409P | 2009-04-23 | 2009-04-23 | |
| US61/171,994 | 2009-04-23 | ||
| PCT/GB2010/050653 WO2010122340A2 (en) | 2009-04-23 | 2010-04-22 | Process 738 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2010240717A1 true AU2010240717A1 (en) | 2011-10-27 |
Family
ID=42224659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010240717A Abandoned AU2010240717A1 (en) | 2009-04-23 | 2010-04-22 | Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-[1- (N-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8450482B2 (https=) |
| EP (1) | EP2421827A2 (https=) |
| JP (1) | JP2012524769A (https=) |
| KR (1) | KR20120007059A (https=) |
| CN (1) | CN102459174A (https=) |
| AR (1) | AR076407A1 (https=) |
| AU (1) | AU2010240717A1 (https=) |
| BR (1) | BRPI1013854A2 (https=) |
| CA (1) | CA2758610A1 (https=) |
| IL (1) | IL215388A0 (https=) |
| MX (1) | MX2011011177A (https=) |
| SG (1) | SG174893A1 (https=) |
| TW (1) | TW201041871A (https=) |
| WO (1) | WO2010122340A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101272613B1 (ko) * | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
| CN108503596A (zh) * | 2018-03-14 | 2018-09-07 | 盐城师范学院 | 一种新的厄洛替尼及其中间体的制备方法 |
| CN108440420A (zh) * | 2018-03-22 | 2018-08-24 | 盐城师范学院 | 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0320793D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| WO2005028469A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005115145A2 (en) * | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
| EP2303276B1 (en) * | 2008-05-13 | 2013-11-13 | AstraZeneca AB | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
| WO2009138779A1 (en) | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline |
-
2010
- 2010-04-22 KR KR1020117027878A patent/KR20120007059A/ko not_active Withdrawn
- 2010-04-22 CA CA2758610A patent/CA2758610A1/en not_active Abandoned
- 2010-04-22 SG SG2011068426A patent/SG174893A1/en unknown
- 2010-04-22 WO PCT/GB2010/050653 patent/WO2010122340A2/en not_active Ceased
- 2010-04-22 US US13/264,217 patent/US8450482B2/en not_active Expired - Fee Related
- 2010-04-22 EP EP10715333A patent/EP2421827A2/en not_active Withdrawn
- 2010-04-22 JP JP2012506579A patent/JP2012524769A/ja active Pending
- 2010-04-22 BR BRPI1013854A patent/BRPI1013854A2/pt not_active IP Right Cessation
- 2010-04-22 AU AU2010240717A patent/AU2010240717A1/en not_active Abandoned
- 2010-04-22 MX MX2011011177A patent/MX2011011177A/es not_active Application Discontinuation
- 2010-04-22 CN CN2010800288080A patent/CN102459174A/zh active Pending
- 2010-04-23 TW TW099112893A patent/TW201041871A/zh unknown
- 2010-04-23 AR ARP100101374A patent/AR076407A1/es not_active Application Discontinuation
-
2011
- 2011-09-26 IL IL215388A patent/IL215388A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201041871A (en) | 2010-12-01 |
| SG174893A1 (en) | 2011-11-28 |
| US20120108814A1 (en) | 2012-05-03 |
| KR20120007059A (ko) | 2012-01-19 |
| WO2010122340A2 (en) | 2010-10-28 |
| MX2011011177A (es) | 2011-11-18 |
| JP2012524769A (ja) | 2012-10-18 |
| WO2010122340A8 (en) | 2011-12-15 |
| CA2758610A1 (en) | 2010-10-28 |
| EP2421827A2 (en) | 2012-02-29 |
| IL215388A0 (en) | 2011-12-29 |
| CN102459174A (zh) | 2012-05-16 |
| WO2010122340A3 (en) | 2011-09-09 |
| BRPI1013854A2 (pt) | 2017-05-16 |
| US8450482B2 (en) | 2013-05-28 |
| AR076407A1 (es) | 2011-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI843372B (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
| JP6141568B1 (ja) | 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩 | |
| ES2733460T3 (es) | Co-cristales de Ibrutinib | |
| CA2243994A1 (en) | 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production | |
| JP6704422B2 (ja) | キナゾリン誘導体の塩およびその製造方法 | |
| SK120898A3 (en) | Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for their production | |
| CN106715439A (zh) | 化合物 | |
| US12227491B2 (en) | EGFR inhibitors | |
| CA2723989C (en) | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline | |
| US8450482B2 (en) | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | |
| JP2002510625A (ja) | Ｍｒｐ１の阻害方法 | |
| CN101115744A (zh) | 制备4-（6-氯-2，3-亚甲基二氧基苯胺基）-7-[2-（4-甲基哌嗪-1-基）乙氧基]-5-四氢吡喃-4-基氧基喹唑啉的方法、中间体及其晶状盐 | |
| KR102409595B1 (ko) | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 | |
| EP3098222B1 (en) | Fused acridine derivative and pharmaceutical composition, preparation method and use thereof | |
| WO2012003413A1 (en) | Novel solid forms of tacedinaline | |
| CN102060875A (zh) | 新型喹唑啉衍生物、制备方法和用途 | |
| HU231012B1 (hu) | Lapatinib sók | |
| HK40037665A (en) | Egfr inhibitors | |
| HK1152867B (en) | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |